Neurizon Therapeutics Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease

Reuters
06/16
Neurizon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease

Neurizon Therapeutics Ltd., a clinical-stage biotech company, has announced promising preclinical results for their drug candidate NUZ-001 in a zebrafish model of Huntington's disease. The study demonstrated that NUZ-001 and its active metabolite, NUZ-001 Sulfone, exhibited significant neuroprotective effects. The treatment successfully prevented developmental and morphological abnormalities, protected against neuronal cell death, restored haemoglobin production, and rescued BDNF expression following the knockdown of the Htt protein. These findings underscore NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms. Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease to further explore its therapeutic potential. These results were presented on June 16, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10836) on June 16, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10